{"entity": "researcher", "timestamp": "2026-08-29T04:31:08.338Z", "family": "Kundu", "given": "Soumi", "initials": "S", "orcid": "0000-0002-0759-3051", "affiliations": ["Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden. soumi.kundu@igp.uu.se."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/630287f4ebb24158ab44ebd423234118.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/630287f4ebb24158ab44ebd423234118"}}, "publications": [{"entity": "publication", "iuid": "736d6408f3ea439a9bb933cbe640ed81", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/736d6408f3ea439a9bb933cbe640ed81.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/736d6408f3ea439a9bb933cbe640ed81"}}, "title": "Integrin \u03b110, a Novel Therapeutic Target in Glioblastoma, Regulates Cell Migration, Proliferation, and Survival.", "authors": [{"family": "Munksgaard Thor\u00e9n", "given": "Matilda", "initials": "M"}, {"family": "Chmielarska Masoumi", "given": "Katarzyna", "initials": "K"}, {"family": "Krona", "given": "Cecilia", "initials": "C"}, {"family": "Huang", "given": "Xiaoli", "initials": "X"}, {"family": "Kundu", "given": "Soumi", "initials": "S", "orcid": "0000-0002-0759-3051", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/630287f4ebb24158ab44ebd423234118.json"}}, {"family": "Schmidt", "given": "Linn\u00e9a", "initials": "L"}, {"family": "Forsberg-Nilsson", "given": "Karin", "initials": "K"}, {"family": "Floyd Keep", "given": "Marcus", "initials": "M"}, {"family": "Englund", "given": "Elisabet", "initials": "E"}, {"family": "Nelander", "given": "Sven", "initials": "S"}, {"family": "Holmqvist", "given": "Bo", "initials": "B"}, {"family": "Lundgren-\u00c5kerlund", "given": "Evy", "initials": "E"}], "type": "journal article", "published": "2019-04-25", "journal": {"title": "Cancers (Basel)", "issn": "2072-6694", "volume": "11", "issue": "4", "issn-l": "2072-6694"}, "abstract": "New, effective treatment strategies for glioblastomas (GBMs), the most malignant and invasive brain tumors in adults, are highly needed. In this study, we investigated the potential of integrin \u03b110\u03b21 as a therapeutic target in GBMs. Expression levels and the role of integrin \u03b110\u03b21 were studied in patient-derived GBM tissues and cell lines. The effect of an antibody-drug conjugate (ADC), an integrin \u03b110 antibody conjugated to saporin, on GBM cells and in a xenograft mouse model was studied. We found that integrin \u03b110\u03b21 was strongly expressed in both GBM tissues and cells, whereas morphologically unaffected brain tissues showed only minor expression. Partial or no overlap was seen with integrins \u03b13, \u03b16, and \u03b17, known to be expressed in GBM. Further analysis of a subpopulation of GBM cells selected for high integrin \u03b110 expression demonstrated increased proliferation and sphere formation. Additionally, siRNA-mediated knockdown of integrin \u03b110 in GBM cells led to decreased migration and increased cell death. Furthermore, the ADC reduced viability and sphere formation of GBM cells and induced cell death both in vitro and in vivo. Our results demonstrate that integrin \u03b110\u03b21 has a functional role in GBM cells and is a novel, potential therapeutic target for the treatment of GBM.", "doi": "10.3390/cancers11040587", "pmid": "31027305", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6521287"}, {"db": "pii", "key": "cancers11040587"}], "notes": [], "created": "2026-08-20T13:39:13.959Z", "modified": "2026-08-20T13:39:14.048Z"}]}